The outlook of companies tied to Viagra's past presents a challenging check here investment picture . While the initial boom generated substantial gains, generic alternatives have significantly eroded revenue. Investing in related pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving healthcare shifts ,